Mild Cognitive Impairment (MCI), Alzheimer'
Conditions
Interventions
None listed
Sponsors
Natural Harmony Clinic Omotesando
Shinsankenkai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1]Patients diagnosed as appropriate for nasal stem cell culture supernatant therapy at participating institutions [2]Persons with normal borderline to moderate Alzheimer's disease and the Hasegawa questionnaire score 10-19 (mild to moderate) [3]Persons who have received a full explanation of the purpose and content of this study and have obtained written informed consent from the subject himself/herself and a surrogate. However, if the attending physician determines that the subject has no problem with the subject's ability to consent, the consent of the surrogate is not required. If the attending physician determines that there is a problem with the subject's own capacity to consent, the consent of the substitute consentor is required, and the consent of the subject himself/herself will be obtained, except in cases where it is difficult to obtain consent from the subject due to the progress of the disease condition. [4]Persons who are able to undergo the examination on the designated examination date. [5]Persons who are deemed appropriate to participate in this study by the principal investigator or collaborating physician.
Exclusion criteria
Exclusion criteria: [1]Patients suffering from dementia other than Alzheimer's disease (vascular dementia, Lewy body dementia, frontotemporal dementia, etc.). [2]Patients diagnosed with Alzheimer's disease who have a disease (medical disease, neurological disease, etc.) that causes dementia-like symptoms prior to Alzheimer's disease. [3]Patients with a significant neurological disease or severe mental disorder other than Alzheimer's disease. [4]Patients who are currently participating in other human clinical trials or who have not yet completed 3 months of participation in other human clinical trials. [5]Other patients who are judged by the principal investigator or cooperating investigator to be inappropriate as subjects for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure (systolic and diastolic)/pulse rate Hematological examination Blood biochemical tests Physician interview/adverse event assessment | — |
Secondary
| Measure | Time frame |
|---|---|
| Hasegawa questionnaire,MCI screening tests | — |
Countries
Japan
Contacts
Public ContactYuji Morita
Medical Corporation Natural Harmony Natural Harmony Clinic Omotesando
Outcome results
None listed